Open an account

Kairos Pharma

KAPA · NYSE American

$0.5837+$0.0136 (+2.39%)TodayMarket closed ·
Prev close $0.5701

KAPA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $49.98 (+8462.6% upside)

Low
$14.14
Now
$0.5837
High
$88.20

Upgrades and downgrades

The latest rating actions, newest first

KAPA analyst upgrades, downgrades and rating actions
FirmDateActionRating
D. Boral CapitalNov 19, 2025MaintainsBuy
D. Boral CapitalNov 4, 2025MaintainsBuy

The case for and against

Updated Apr 17, 2026

Bull case

Kairos Pharma Ltd is positioned favorably due to its ongoing advancements in the oncology pipeline, marked by significant clinical milestones and strong financial discipline. The company has secured funding, including Department of Defense grants, which further bolster its capital structure and support investigative studies on drug resistance, allowing for sustained operational execution without significant dilution. Notably, the interim clinical results for ENV105 demonstrated an impressive 86% clinical benefit rate with favorable safety profiles, highlighting the potential for the company’s therapeutics in a competitive market.

Bear case

Kairos Pharma Ltd, a clinical-stage biopharmaceutical company, reported a lack of product revenues, indicating ongoing challenges in commercializing its therapeutics designed for cancer treatment. For the quarter ending June 30, 2025, the company incurred a net loss of approximately $1.4 million, contributing to a cumulative net loss of $2.7 million for the first half of 2025. This absence of revenue generation alongside significant financial losses raises concerns regarding the company's ability to achieve profitability in the near term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.